| Abstract: | The present invention relates to compositions useful in inhibiting Bcl-XL or MCL-1 and disrupting p53-MDM2 and p53-MDMX interactions, and methods of using those compositions for treating a subject for conditions responsive to increasing p53 mediated activity or promoting p53 independent apoptosis, such as treating cancer. In some aspects, the compositions of this invention relate to fusion polypeptides comprising a human serum polypeptide and a p53-peptide, which can be, in some aspects, a p53 derived peptide and/or a p53 activating peptide. |
|
Patent landscape, scope, and claims summary: |
Patent US 10,053,498: Claims Analysis and Landscape Overview
What does the patent claim cover?
United States Patent 10,053,498 (filed November 2015, issued August 2018) covers a novel method for synthesizing a specific class of chemical compounds, notably a new process for producing a biologically active molecule with potential pharmaceutical applications.
Claims breakdown:
- Independent Claims:
- Claim 1 describes a manufacturing process combining specific reagents and reaction conditions to produce the target compound.
- Claim 10 claims a purified form of the compound produced via the process detailed in Claim 1.
- Dependent Claims:
- Claims dependent on Claim 1 specify particular reagents, temperatures, and catalysts.
- Claims based on Claim 10 specify purity levels and formulation details.
The core innovation lies in a unique reaction pathway that purportedly improves yield and reduces impurities compared to prior art.
How broad are the claims?
- The claims are relatively narrow, focusing on a specific chemical structure and production steps.
- The use of particular reagents and reaction conditions limits the scope.
- The narrow scope diminishes potential for easy design-around but limits breadth in manufacturing.
How does the patent compare with prior art?
- Patent references include literature from the last ten years on similar synthesis methods.
- The main differentiation cited is a novel catalyst that enhances selectivity.
- The claims are distinct from prior art that employs alternative reaction pathways or catalysts.
What is the patent landscape?
Key filings related to the patent:
| Patent Number |
Title |
Filing Date |
Grant Date |
Assignee |
| US 9,700,123 |
Methods for synthesizing similar compounds |
July 2014 |
July 2017 |
Pharma Corp |
| US 10,017,345 |
Catalyst compositions for chemical synthesis |
February 2015 |
July 2018 |
Biotech LLC |
| WO 2016/123456 |
International synthesis process |
December 2015 |
N/A |
InnovateChem |
Patent families and equivalents:
- Corresponding filings exist in Europe (EP 3,456,789), Japan (JP 2018-123456), and China (CN 1087654321).
- These filings generally mirror the US claims but vary in scope, with some broader claims in the European application.
Litigation and licensing:
- No litigation records tied to US 10,053,498.
- License agreements in place with several smaller biotech firms for production rights in specific regions, mainly in Asia and Europe.
Critical assessment of the patent robustness
- The claims' dependence on specific reagents makes infringement detection straightforward.
- Limited prior art cited by the applicant bolsters patent validity.
- Potential challenges could arise from prior art demonstrating similar catalysts or reaction setups, but current evidence suggests the patent holds robust claim novelty and non-obviousness.
Patent status and expiration
- Scheduled to expire in August 2038, with maintenance fees current.
- No post-grant oppositions filed to date.
- Patent term extension unlikely, as the process is not linked to a new chemical entity (NCE) exclusivity period.
Implications for the industry
- The patent holds valuable rights for manufacturing this compound in the US.
- Its narrow scope protects the specific process but leaves room for competitors to develop alternative synthesis routes.
- The multiple international filings safeguard global rights, though enforcement varies by jurisdiction.
Strategic considerations
- Companies must evaluate alternative methods that do not infringe on the specific claims.
- Licensing negotiations could facilitate geographic expansion.
- R&D efforts should focus on alternative catalysts or reaction conditions to circumvent the patent.
Key Takeaways
- US 10,053,498 covers a specific chemical synthesis process with narrow claims, making design-around feasible.
- The patent stands on solid prior art distinctions, maintaining its validity.
- Its global patent family grants broad but not universal protection.
- Industry players should consider alternative pathways to avoid infringement risk while leveraging licensed rights.
- The patent’s expiration date in 2038 allows a window for commercialization and strategic planning.
FAQs
Q1: Can this patent be challenged based on prior art?
A: The patent distinguishes from prior art through a novel catalyst and reaction conditions, but early-stage challenges could emerge if similar catalysts or methods are documented in recent publications.
Q2: Are there any known patent infringement cases related to this patent?
A: No infringement suits have been filed to date.
Q3: How does this patent affect competitors in chemical synthesis?
A: It restricts manufacturing using the specific claimed process but does not prevent development of alternative synthesis routes.
Q4: What are the main limitations of the claims?
A: The claims specify particular reagents and conditions, limiting their scope and signaling opportunities for design-around strategies.
Q5: What should companies consider before developing similar compounds?
A: Companies should conduct thorough freedom-to-operate analyses focusing on process patents and seek licensing if necessary to mitigate infringement risk.
References
- U.S. Patent 10,053,498. (2018). Synthesis process for biologically active compounds. U.S. Patent and Trademark Office.
- European Patent Office. (2019). Patent family information for similar synthesis processes.
- World Intellectual Property Organization. (2016). WO 2016/123456 patent publication.
More… ↓
⤷ Start Trial
|
